We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

HEMOCUE AB

HemoCue AB develops, produces, and markets medical diagnostic products for point of care testing (POC) markets. Its p... read more Featured Products: More products

Download Mobile App




Dengue Patients’ Hemoglobin Concentrations Compared by POC and CBC

By LabMedica International staff writers
Posted on 06 Sep 2021
Print article
Image: The HemoCue Hb 201+ System Analyzer has become a standard in hemoglobin point-of-care testing (Photo courtesy of HemoCue AB)
Image: The HemoCue Hb 201+ System Analyzer has become a standard in hemoglobin point-of-care testing (Photo courtesy of HemoCue AB)
Dengue is a mosquito-borne viral infection that is mainly found in tropical and sub-tropical climates. The natural history of dengue has the unique characteristic of plasma leakage that results in hemoconcentration as well as vasculopathy and thrombocytopenia that result in bleeding.

Hematocrit monitoring is a crucial tool to guide management in dengue patients. Microhematocrit adjunct with a complete blood count (CBC) to monitor dengue patients were traditionally performed to decrease the frequency of venipuncture. However, microhematocrit is currently less preferred to the point-of-care hemoglobin monitoring tools to measure red cells in other diseases.

A team of medical scientists at the Ramathibodi Hospital (Bangkok, Thailand) evaluated the relationship between hemoglobin measured by point-of-care hemoglobin (POC-Hb) testing and hematocrit measured by the automated method in adult dengue patients. A total of 44 dengue patients were enrolled. Twenty-nine patients (65.9%) were female, with a median age of 31 years (interquartile range 22–41). Of the enrolled patients, 30 (68.2%), 11 (25.0%), and three (6.8%) were classified as dengue without warning signs, with warning signs, and severe dengue, respectively. Seven patients (15.9%) had hemoconcentration, and five patients (11.3%) had bleeding.

The team measured a CBC by Mindray BC-6800Plus (Mindray, Shenzhen, China) at Ramathibodi Hospital, and Sysmex XN-3000 (Sysmex, Kobe, Japan) at Chakri Naruebodindra Medical Institute. POC-Hb testing was performed on capillary blood and read by the HemoCue Hb 201+ (HemoCue AB, Ängelholm, Sweden). POC-Hb testing was conducted by three physicians who were trained on the use of the device. Hemoconcentration was defined by an increase of ≥20% in hematocrit compared with a convalescent value. A total of 216 pairs of POC-Hb and CBC were evaluated.

The investigators reported that the medians of hemoglobin and hematocrit at dengue presentation were 13.8 g/dL and 41.6%, respectively. The medians of mean corpuscular volume (MCV) and platelets were 87.0 fL and 98,500/mm3, respectively. The team found a significant positive correlation was observed between hemoglobin measured by POC-Hb testing and hematocrit measured by an automated CBC. Bland-Altman analysis between hemoglobin measured by POC-Hb testing and an automated CBC showed a bias of -0.43. Using the cutoff of POC-Hb ≥20% as a criteria for hemoconcentration, the sensitivity and specificity of hemoconcentration detected by POC-Hb device were 71.4% and 100.0%, respectively.

The authors concluded that hemoglobin measurement using POC-Hb testing adjunct with CBC monitoring can be used to monitor plasma leakage as well as hemorrhage in dengue patients. The use of POC-Hb testing is less invasive and requires less blood compared to venipuncture for CBC evaluation. The study was published on August 16, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Ramathibodi Hospital
Mindray
Sysmex
HemoCue AB


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.